Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Core Insights - Biohaven Ltd. reported results from a Phase 2 proof-of-concept study for BHV-7000 aimed at treating major depressive disorder (MDD), which did not meet its primary endpoint of reducing depressive symptoms compared to placebo [1] - Some positive trends were observed in specific subgroups, particularly those with more severe depression, although the overall efficacy was not supported [1] - The safety profile of BHV-7000 was favorable, with adverse events primarily mild to moderate, and the most common adverse events being headache (10.7% in BHV-7000 vs. 9.9% in placebo) and nausea (4.2% in BHV-7000 vs. 5.6% in placebo) [1] - The company plans to focus its resources on key therapeutic areas such as immunology, obesity, and epilepsy, rather than pursuing further psychiatric clinical trials for BHV-7000 [1] Company Overview - Biohaven is a biopharmaceutical company dedicated to developing life-changing therapies across various therapeutic areas, including immunology, obesity, neuroscience, and oncology [3] - The company is advancing its innovative portfolio, which includes programs targeting Kv7 ion channels for epilepsy and mood disorders, as well as extracellular protein degraders for immunological diseases [3] - Biohaven's management will present updates on its clinical programs at the upcoming J.P. Morgan Healthcare Conference in January 2026, highlighting ongoing studies and new developments [2][5]